Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Oruka Therapeutics, Inc. (ORKA) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 400 shares for the 12-month period ending 2017-12-31, per its 10-K filed 2019-02-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2019-02-27
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2017-12-31 was 0.00 shares.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2017-09-30 was 0.00 shares.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2017-06-30 was 0.00 shares.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2017-03-31 was 400.00 shares, a 15.07% decline year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2017 was 400.00 shares, a 15.07% decline from fiscal 2016.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2016 was 471.00 shares, a 95.07% decline from fiscal 2015.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2015 was 9.55K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|---|
| 2017-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2019-02-27 | 0.00 shares derived: sum of 3 quarters · filed 2019-02-27 | 400.00 shares 10-K · filed 2019-02-27 |
| 2017-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | 0.00 shares derived: sum of 2 quarters · filed 2017-11-09 | 400.00 shares 10-Q · filed 2017-11-09 | 400.00 shares derived: sum of 4 quarters · filed 2018-03-22 |
| 2017-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | 400.00 shares 10-Q · filed 2017-08-03 | 400.00 shares derived: sum of 3 quarters · filed 2018-03-22 | 400.00 shares derived: sum of 4 quarters · filed 2018-03-22 |
| 2017-03-31 | 400.00 shares 10-Q · filed 2017-05-15 | 400.00 shares derived: sum of 2 quarters · filed 2018-03-22 | 400.00 shares derived: sum of 3 quarters · filed 2018-03-22 | 400.00 shares derived: sum of 4 quarters · filed 2018-03-22 |
| 2016-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-22 | 0.00 shares derived: sum of 2 quarters · filed 2018-03-22 | 0.00 shares derived: sum of 3 quarters · filed 2018-03-22 | 471.00 shares 10-K · filed 2018-03-22 |
| 2016-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | 0.00 shares derived: sum of 2 quarters · filed 2016-11-14 | 471.00 shares 10-Q · filed 2016-11-14 | 9.16K shares derived: sum of 4 quarters · filed 2017-03-21 |
| 2016-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | 471.00 shares 10-Q · filed 2016-08-09 | 9.16K shares derived: sum of 3 quarters · filed 2017-03-21 | 3.98K shares derived: sum of 4 quarters · filed 2017-03-21 |
| 2016-03-31 | 471.00 shares 10-Q · filed 2016-05-11 | 9.16K shares derived: sum of 2 quarters · filed 2017-03-21 | 3.98K shares derived: sum of 3 quarters · filed 2017-03-21 | |
| 2015-12-31 | 8.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | 3.51K shares derived: sum of 2 quarters · filed 2017-03-21 | 9.55K shares 10-K · filed 2017-03-21 | |
| 2015-09-30 | -5.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | 862.00 shares 10-Q · filed 2015-11-12 | ||
| 2015-06-30 | 6.04K shares 10-Q · filed 2015-08-11 | |||
| 2014-09-30 | 0.00 shares 10-Q · filed 2014-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |